Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance

BACKGROUND: Although significant advances have been made recently to characterize the biology of pancreatic ductal adenocarcinoma (PDAC), more efforts are needed to improve our understanding and to face challenges related to the aggressiveness, high mortality rate and chemoresistance of this disease...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:EBioMedicine
Autores principales: Kaoutari, Abdessamad El, Fraunhoffer, Nicolas A, Hoare, Owen, Teyssedou, Carlos, Soubeyran, Philippe, Gayet, Odile, Roques, Julie, Lomberk, Gwen, Urrutia, Raul, Dusetti, Nelson, Iovanna, Juan
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8054161/
https://ncbi.nlm.nih.gov/pubmed/33862584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2021.103332
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares